Question 5: How do we characterize and localize Astigmatisms within the optical pathway? with: Larry Patterson, MD Mitch Jackson, MD Cynthia Matossian, MD Neda Shamie, MD Toby Tyson, MD Thanks to Marco for letting me re-post this; I realize the panel and the video was aimed at OMDs primarily, but so much of the discussion is highly relevant to ODs. -- adam ----- Other videos from the Power Forum III: Question 1: How does data from Angles Alpha & Kappa, Corneal SA, Coma, pupil size, and Corneal vs. Lenticular Astigmatism improve your premium IOL selections and outcomes? Question 2: What wavefront data should you use to select EDOF IOLs for patients? Question 3: What are the multi-function benefits of using an integrated Wavefront Aberrometer, registered on the patient’s optical center? Question 4: When OSD is discovered prior to surgery, should you postpone the procedure for treatment, or stabilize the tear film, then proceed with surgery? Question 5: How do we characterize and localize Astigmatisms within the optical pathway? Question 6: How do you manage patient expectations and IOL selection? Question 7: How do we measure OPD ROI and monetize the advanced diagnostic test regimen?